Please ensure Javascript is enabled for purposes of website accessibility

3 Top Medical Device Stocks for Growth Investors

By Keith Speights - Apr 9, 2017 at 6:41AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Looking for high growth? Check out medical device stocks Align Technology, Edwards Lifesciences, and Intuitive Surgical.

Many medical device stocks are boring. Low growth and little excitement aren't uncommon among stocks in the industry. But not all of them fit that mold.

Investors looking for solid growth should find plenty to like about Align Technology (ALGN 4.51%), Edwards Lifesciences (EW 2.42%), and Intuitive Surgical (ISRG 2.69%). These companies operate in radically different parts of the broader medical device market, but each of these stocks could be poised to grow. Here's why.

Man pointing to growth chart on screen

Image source: Getty Images.

Align Technology: A clear leader in dental care

If Align Technology gets its wish, those awkward metal dental braces will become a thing of the past. The company's Invisalign clear dental aligners are practically invisible and just as effective at straightening teeth as braces in most cases.

Align's earnings have more than tripled over the past five years thanks to the growing popularity of Invisalign. In addition, the company's intraoral scanners, which dental professionals can use to create 3D models of patients' teeth, are becoming an increasingly important source of revenue for Align. 

There are three key opportunities for Align to achieve even greater growth in the future. One is international expansion, especially in developing markets with increasing middle-class populations. Align is also targeting general practitioner dentists, who see many more patients who are candidates for Invisalign than orthodontists do. Innovation presents another pathway to growth, as Align develops clear aligners for more complex cases of malocclusion. 

Edwards Lifesciences: All about the heart

Edwards Lifesciences is a global leader in artificial heart valves and systems that monitor patients' cardiovascular functions. The company was a pioneer in developing transcatheter aortic valve replacement (TAVR) therapy. 

Edwards' earnings have nearly doubled over the past five years. This growth was primarily fueled by increasing demand for its Sapien line of heart valves. Safety has been an important part of the company's products' value proposition. For example, studies showed that Edwards' Sapien 3 valve reduced mortality and strokes by 75% compared to surgery in intermediate-risk patients. 

The company should benefit from tremendous growth in the TAVR market, which is expected to double to more than $5 billion by 2021. That growth projection is based only on treatment of patients with severe symptomatic aortic stenosis. Edwards thinks that it can achieve further growth by bringing its less-invasive treatment options to asymptomatic patients. 

Intuitive Surgical: Rise of the robots

If someone you know has had a hysterectomy or prostatectomy, there's a pretty good chance that Intuitive Surgical's da Vinci robotic surgical system could have been used in the surgery. The system was used to perform 204,000 hysterectomies and 92,000 radical prostatectomies in the U.S. last year. 

Intuitive Surgical's earnings are up more than 75% since 2014. The company ran into something of a rough patch for a while due to concerns about the safety of its robotic surgical technology. However, Intuitive Surgical has benefited from an increasing number of studies showing the value and safety of da Vinci. 

One of those studies has contributed to Intuitive Surgical's rapid growth in the hernia surgery market. Research found that the average hospital stay for patients who had hernia repairs with da Vinci was 2.5 days shorter than the stay for patients undergoing open surgery, with similar readmission rates. 

Expanding into new surgical procedures presents a significant opportunity for Intuitive Surgical to grow in the future. And while the company already has a large international presence, there's still plenty of room to grow in markets outside the U.S.

Growth isn't cheap

Align Technology, Edwards Lifesciences, and Intuitive Surgical are bringing tremendous technological innovation to their respective types of medical devices. Their stocks appear poised for significant growth in the future.

However, all three stocks command premium valuations: Align Technology's shares trade at 32 times expected earnings. Edwards Lifesciences claims a forward earnings multiple of over 24. Intuitive Surgical stock trades at nearly 29 times expected earnings. As investors have seen with previous technology revolutions, growth isn't always cheap. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Edwards Lifesciences Corporation Stock Quote
Edwards Lifesciences Corporation
EW
$97.39 (2.42%) $2.30
Intuitive Surgical, Inc. Stock Quote
Intuitive Surgical, Inc.
ISRG
$206.10 (2.69%) $5.39
Align Technology, Inc. Stock Quote
Align Technology, Inc.
ALGN
$247.34 (4.51%) $10.67

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.